Funding for this research was provided by:
European Regional Development Fund (V-630-1-301-2013/185)
Received: 11 September 2020
Accepted: 20 November 2020
First Online: 2 December 2020
Ethics approval and consent to participate
: This study was carried out in accordance with the University Medical Centre Utrecht, Biobank Regulations, which are in compliance with the applicable national and international laws and regulations. These regulations permit the use of ‘residual material from diagnostic testing’ for research, unless the patient objects (Article 8, ‘no objection’ procedure). None of the included patients objected the use of their serum. The protocol was approved by the Biobank Research Ethics Committee of the University Medical Centre Utrecht under the protocol number 18-428.
: Not applicable.
: S. Rohwer, B. Brix and W. Suer are employees of EUROIMMUN. The research position of A. Ehlers is partially funded by EUROIMMUN. Other authors have no competing interests to declare.